Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1487MR)

This product GTTS-WQ1487MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1487MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1041MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ10810MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ8887MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ8899MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ13021MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10172MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ9968MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ10658MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW